Catabasis

$2.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.13 (-5.49%) Today
$0.00 (0.00%) As of 8:11 PM UTC after-hours

Why Robinhood?

You can buy or sell Catabasis and other stocks, options, and ETFs commission-free!

About CATB

Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy.

CEO
Jill C. Milne
Employees
20
Headquarters
Boston, Massachusetts
Founded
2008
Market Cap
51.82M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
396.48K
High Today
$2.35
Low Today
$2.15
Open Price
$2.35
Volume
771.61K
52 Week High
$8.59
52 Week Low
$1.25

CATB Earnings

-$0.64
-$0.43
-$0.21
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 11, After Hours

You May Also Like

GXGXW
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure